Location of Repository

Clinical potential of brodalumab in the management of psoriasis: the evidence to date

By Sandoval LF, Williams B and Feldman SR

Abstract

Laura F Sandoval,1 Brooke Williams,1 Steven R Feldman1–3 1Department of Dermatology, Center for Dermatology Research, Wake Forest School of Medicine, Winston-Salem, NC, USA; 2Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC, USA; 3Department of Public Health Sciences, Wake Forest School of Medicine, Winston-Salem, NC, USA Abstract: Brodalumab is an anti-IL-17 receptor monoclonal antibody currently in development for the treatment of moderate-to-severe plaque psoriasis. With many systemic psoriasis therapies to choose from, and several newer agents in development, physicians need up to date evidence for the use of these drugs. A PubMed search was conducted through August 1, 2014 to identify randomized controlled trials and systematic reviews of brodalumab for the treatment of psoriasis. Results of Phase I and II trials, as well as a few smaller studies, have provided promising data on efficacy, safety, health-related quality of life, pharmacokinetics, and changes in lesional skin. Early Phase III data continue to support the use of brodalumab as a potentially valuable option for the treatment of psoriasis. Keywords: anti-interleukin-17, psoriasis, biologic agents, efficacy, safety, systemic therap

Topics: Specialties of internal medicine, RC581-951
Publisher: Dove Medical Press
Year: 2015
OAI identifier: oai:doaj.org/article:e460669aee4546c284912a052ce96d84
Journal:
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • https://doaj.org/toc/2230-326X (external link)
  • http://www.dovepress.com/clini... (external link)
  • https://doaj.org/article/e4606... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.